Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-08

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)

This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859

Pmm2-CDG Phosphomannomutase 2 Deficiency

ENROLLING_BY_INVITATION PHASE2

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

NCT05549219

Pmm2-CDG Phosphomannomutase 2 Deficiency

COMPLETED PHASE2

A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

NCT00077662

Glycogen Storage Disease Type II

COMPLETED

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

NCT01665326

Pompe Disease

RECRUITING

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

NCT00113035

Pompe Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 3- 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients routine therapy is dictated by this protocol. The International Co-Operative Ataxia Rating Scale (ICARS) is to be performed every 3 months as an optional assessment. No randomization will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phosphomannomutase 2 Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent/assent by the patient and/or their legally authorized representative
* Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests
* Willing and able to adhere to study requirements described in the protocol and consent/assent documents

Exclusion Criteria

* Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)
* Currently using investigational drug
* Blood loss of ≥ 250 mL or donated blood within 56 days, or donated plasma within 7 days before study screening

Eligible Sex

ALL

Accepts Healthy Volunteers

No